Late-onset cerebellar ataxia: case report of a new CNV on TTBK2 gene as possible cause of SCA-11
Objective: To describe a case of spinocerebellar ataxia type 11 caused by the copy number variant 43008859_43075833 on the TKKB2 gene Background: The spinocerebellar ataxias…Robust methods for missing covariates in longitudinal studies with application to biomarker research in Parkinson’s disease dementia
Objective: We propose a nonparametric method for handling different types of missing covariates in longitudinal studies. We show that the proposed method outperforms multiple standard…A Report from Japan on Initial Experiences with Adaptive Deep Brain Stimulation Therapy for Patients with Advanced Parkinson’s Disease
Objective: Here we present our initial experience with deep brain stimulation therapy (DBS) for Parkinson's disease (PD) using the closed-loop system. Background: Although DBS is…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Co-contractions as a Biomarker for DBS Efficacy in Dystonia
Objective: Deep brain stimulation of the globus pallidus interna (GPi-DBS) is a treatment option for medication-refractory dystonia. However, the clinical outcome after DBS-GPi is variable,…APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation
Objective: There were accumulating evidence proving that rifampicin could protect neurons from apoptosis in Parkinson's disease in-vitro model by regulating SUMO modification of α-synuclein. However,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.